
11 - 50 employees
Founded 2008
🏥 Healthcare
💼 Consulting
🎖️ Defense
🔥 Funding within the last year
💰 $200M Post-IPO Equity - Immuneering on 2025-09
Healthcare • Consulting • Defense
Immuneering Corporation is a clinical-stage biotechnology company developing a novel class of oncology therapies called Deep Cyclic Inhibitors, which use rhythmic dosing to outpace cancer adaptation, improve tolerability, and extend patient survival and quality of life. The company advances a pipeline through clinical trials, collaborates with partners, and emphasizes scientific research and publications to transform cancer treatment while reducing side effects of traditional continuous-inhibition therapies.
🕒 July 9
Director of Pharmacovigilance at Immuneering leading safety surveillance strategies across oncology programs. Building the PV function at a clinical-stage biopharmaceutical company.
🇺🇸 United States – Remote
💵 $280k - $350k / year
🔥 Funding within the last year
💰 $200M Post-IPO Equity - Immuneering on 2025-09
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 6%